Read the online version.



Embarc Benefit Protection new gene therapy inclusion

Skysona for cerebral adrenoleukodystrophy (CALD)

This communication is being sent to medical clients with Embarc Benefit Protection® and their aligned producers.

Embarc Benefit Protection is Cigna’s gene therapy network solution designed to make high-cost and potentially life-changing drugs more accessible to patients and the cost more affordable and predictable for employers.

We are committed to developing the most robust network solution possible and are continually assessing the gene therapy pipeline for new drugs. Drugs that are currently part of the Embarc Benefit Protection solution are Luxturna®, Zolgensma® and Zynteglo®, and we are pleased to announce the newest addition, Skysona®.

Clock Icon Skysona overview

Skysona is a new gene therapy drug from bluebird bio, Inc., for patients living with cerebral adrenoleukodystrophy (CALD), a rare and deadly neurologic disease. Early diagnosis and treatment of CALD is essential because nearly half of patients who do not receive treatment die within five years of symptom onset.*

According to bluebird bio, adrenoleukodystrophy (ALD) is estimated to affect approximately 1 in 20,000 to 1 in 30,000 newborn males. ALD progresses to CALD in approximately 40% of affected boys and in a smaller number of affected men.**

Without Embarc Benefit Protection, the client cost for the one therapeutic required dose of Skysona could be $3 million.*** As of 12/01/2022, we are pleased to include Skysona as part of Embarc Benefit Protection while maintaining our predictable price of $0.99 per member per month (PMPM).

If you have any questions, please contact your Cigna representative.